to screen prioritized FDA-approved drugs against SARS-CoV-2 in vitro

Grant number: INV-006099

Grant search

Key facts

  • Disease

    COVID-19
  • start year

    2020
  • Known Financial Commitments (USD)

    $717,958
  • Funder

    Gates Foundation
  • Principal Investigator

    N/A

  • Research Location

    United States of America
  • Lead Research Institution

    University of Maryland, Baltimore
  • Research Priority Alignment

    N/A
  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Prophylactic use of treatments

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

N/A

Publicationslinked via Europe PMC

Last Updated:41 minutes ago

View all publications at Europe PMC

SARS-CoV-2 ORF8 modulates lung inflammation and clinical disease progression.

Pyronaridine tetraphosphate is an efficacious antiviral and anti-inflammatory active against multiple highly pathogenic coronaviruses.

Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms.